Creative Biolabs Assists Global Clients in Viral Vector Vaccine Design and Vaccine Target Validation

May 27 18:18 2019

New York, May 27, 2019 Creative Biolabs, a biotech company engaged on vaccine technology, now provides Viral Vector Vaccine Design and Vaccine Target Validation services for global clients, to assist clients in exploiting a wide array of novel technologies to produce safer and more efficacious vaccines.


1 Viral Vector Vaccine Design Services

Viral vector-based vaccines present advantages over traditional vaccines in that they can enhance a broad range of immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. The viral vector vaccine design services in Creative Biolabs are characterized by high efficiency gene transduction, highly specific delivery of genes to target cells, which can induce both humoral and cell-mediated immune responses with improved efficacy and safety and reduced administration dose. The services also enable large-scale manufacturing with potential targets ranging from cancers to a vast number of infectious diseases.  When producing viral vector vaccine, it is important to assess the potential effects by understanding epidemiological and virological characteristics.  Creative Biolabs offers multiple vectors for different virus including retrovirus, lentivirus, vaccinia virus, adenovirus, adeno-associated virus, cytomegalovirus, sendai virus, for customers’ specific needs.


2 Vaccine Target Validation

The Discovery of Vaccine Target aims to locate highly polymorphic genes that may encode immunogenic antigens by using sequencing and comparisons of multiple isolates of the same species. Scientists in Creative Biolabs can use indirect or hypothetical driving methods to pre-select a smaller series of potential antigen candidates (e.g., T cell epitope prediction, proteomics, sequence analysis, serum antibody binding to pathogen encoded cDNA libraries or localization and function prediction algorithms).


“We focus on rapid mutate viral pathogens, which are currently the main targets of vaccine research. Our next generation sequencing enables a broad range of applications including reversible terminator sequencing (Illumina), 454 Pyrosequencing, ion torrent semiconductor sequencing, sequencing by ligation (SOLiD). NGS has allowed us to sequester DNA and RNA faster and cheaper than ever before.” Said a scientist in Creative Biolabs.


As a leading service provider that focuses on all kinds of Vaccine Technology, Creative Biolabs also provides a wide range of Vaccine Design services to meet customers’ requirements. More detailed information on vaccine technology can be reached at



Creative Biolabs, headquartered in New York, is a leading custom service provider in the field of vaccine development, preclinical assessment and GMP manufacturing. The technical and regulatory experts can provide vaccine developers with a full range of products and vaccine related services. Traditional and the most updated genetic engineering technologies are combined to efficiently produce highly immunogenic and safe vaccines to address emergency unmet medical needs. The service portfolio includes a full range of vaccine design for client’s specific requirements that covers vaccine target validation, vaccines targeting bacterial, viral, fungal, parasites, cancer markers and more. Formulation optimization services are also available for maximum potency, including improving delivery systems, a great variety of adjuvant products and services like PRR Ligands scanning and adjuvants synthesis.


Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States